![Alzheimer's Disease Market Infographic](https://i0.wp.com/www.delveinsight.com/blog/wp-content/uploads/2019/11/Alzhiemers.jpg?fit=1424%2C3698&ssl=1)
It’s is the end of Alzheimer’s Awareness Month, but our hope for a cure for this disease will not end.
They may not remember us, but we need to remember that Alzheimer’s battle is not theirs alone, but all of ours.
Nov 29, 2019 | Reading Time: < 1 minute
It’s is the end of Alzheimer’s Awareness Month, but our hope for a cure for this disease will not end.
They may not remember us, but we need to remember that Alzheimer’s battle is not theirs alone, but all of ours.
The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KINSUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanema...
Find MoreIMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...
Find MoreTakeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!